News | November 02, 2023
Zydus acquires UK based LiqMeds Group
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
With the establishment of five different precious metals alloy powder production methods
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Subscribe To Our Newsletter & Stay Updated
